Insys Therapeutics Company Profile (NASDAQ:INSY)

About Insys Therapeutics (NASDAQ:INSY)

Insys Therapeutics logoInsys Therapeutics, Inc. is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company's product Subsys, is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and a single-use product that delivers fentanyl, an opioid analgesic, for transmucosal absorption underneath the tongue. The Company markets Subsys through its field sales force focused on supportive care physicians in the United States. Subsys delivers a liquid fentanyl formulation in approximately 100, 200, 400, 600, 800, 1,200 and 1,600 micrograms (mcg) dosages. The Company's lead dronabinol product candidate is Syndros, which is under review for approval at the Food and Drug Administration. In addition, the Company is evaluating sublingual spray, inhaled and intravenous formulations of dronabinol in preclinical studies.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:INSY
  • CUSIP: N/A
  • Web:
  • Market Cap: $539.41 million
  • Outstanding Shares: 72,696,000
Average Prices:
  • 50 Day Moving Avg: $9.04
  • 200 Day Moving Avg: $10.90
  • 52 Week Range: $7.27 - $15.06
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -11.41
  • P/E Growth: -0.85
Sales & Book Value:
  • Annual Revenue: $191.17 million
  • Price / Sales: 2.86
  • Book Value: $3.66 per share
  • Price / Book: 2.06
  • EBITDA: ($8,730,000.00)
  • Net Margins: -9.63%
  • Return on Equity: -3.02%
  • Return on Assets: -2.34%
  • Current Ratio: 3.13%
  • Quick Ratio: 2.81%
  • Average Volume: 606,222 shs.
  • Beta: 0.95
  • Short Ratio: 20.18

Frequently Asked Questions for Insys Therapeutics (NASDAQ:INSY)

What is Insys Therapeutics' stock symbol?

Insys Therapeutics trades on the NASDAQ under the ticker symbol "INSY."

When did Insys Therapeutics' stock split? How did Insys Therapeutics' stock split work?

Insys Therapeutics shares split before market open on Monday, March 31st 2014. The 3-2 split was announced on Tuesday, March 4th 2014. The newly minted shares were distributed to shareholders after the market closes on Friday, March 28th 2014. An investor that had 100 shares of Insys Therapeutics stock prior to the split would have 150 shares after the split.

How were Insys Therapeutics' earnings last quarter?

Insys Therapeutics, Inc. (NASDAQ:INSY) posted its quarterly earnings data on Thursday, August, 3rd. The company reported $0.03 EPS for the quarter, topping the Zacks' consensus estimate of ($0.09) by $0.12. The firm earned $42.60 million during the quarter, compared to analyst estimates of $36.90 million. Insys Therapeutics had a negative net margin of 9.63% and a negative return on equity of 3.02%. The firm's revenue was down 38.4% on a year-over-year basis. During the same quarter last year, the firm posted $0.13 EPS. View Insys Therapeutics' Earnings History.

Where is Insys Therapeutics' stock going? Where will Insys Therapeutics' stock price be in 2017?

4 brokerages have issued twelve-month price targets for Insys Therapeutics' stock. Their predictions range from $10.00 to $14.00. On average, they anticipate Insys Therapeutics' stock price to reach $12.67 in the next year. View Analyst Ratings for Insys Therapeutics.

Who are some of Insys Therapeutics' key competitors?

Who are Insys Therapeutics' key executives?

Insys Therapeutics' management team includes the folowing people:

  • Steven J. Meyer, Independent Chairman of the Board
  • Saeed Motahari, President, Chief Executive Officer, Director
  • Andrew G. Long, Chief Financial Officer
  • Franc Del Fosse, General Counsel, Corporate Secretary
  • John N. Kapoor Ph.D., Non-Independent Director
  • Rohit Vishnoi, Director
  • Patrick P. Fourteau, Independent Director
  • Pierre Lapalme, Independent Director
  • Brian Tambi, Independent Director

How do I buy Insys Therapeutics stock?

Shares of Insys Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Insys Therapeutics' stock price today?

One share of Insys Therapeutics stock can currently be purchased for approximately $7.53.

MarketBeat Community Rating for Insys Therapeutics (NASDAQ INSY)
Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  227 (Vote Outperform)
Underperform Votes:  161 (Vote Underperform)
Total Votes:  388
MarketBeat's community ratings are surveys of what our community members think about Insys Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Insys Therapeutics (NASDAQ:INSY) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Hold Ratings, 2 Buy Ratings
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $12.67 (68.22% upside)
Consensus Price Target History for Insys Therapeutics (NASDAQ:INSY)
Price Target History for Insys Therapeutics (NASDAQ:INSY)
Analysts' Ratings History for Insys Therapeutics (NASDAQ:INSY)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/11/2017Royal Bank Of CanadaReiterated RatingOutperform -> Outperform$14.00N/AView Rating Details
8/3/2017Oppenheimer Holdings, Inc.Reiterated RatingHoldMediumView Rating Details
7/26/2017Piper Jaffray CompaniesSet Price TargetHold$10.00MediumView Rating Details
6/9/2017Jefferies Group LLCReiterated RatingBuy$14.00LowView Rating Details
4/14/2016Janney Montgomery ScottInitiated CoverageBuy$22.00N/AView Rating Details
3/9/2016JMP SecuritiesLower Price TargetMarket Outperform$38.00 -> $30.00N/AView Rating Details
(Data available from 10/18/2015 forward)


Earnings History for Insys Therapeutics (NASDAQ:INSY)
Earnings by Quarter for Insys Therapeutics (NASDAQ:INSY)
Earnings History by Quarter for Insys Therapeutics (NASDAQ INSY)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/3/2017Q2 2017($0.09)$0.03$36.90 million$42.60 millionViewListenView Earnings Details
5/9/2017Q1 2017($0.10)($0.09)$37.78 million$35.92 millionViewListenView Earnings Details
4/3/2017Q4 2016$0.00$0.03$52.08 million$54.86 millionViewN/AView Earnings Details
11/3/2016Q316$0.02$0.07$55.97 million$55.20 millionViewN/AView Earnings Details
8/3/2016Q216$0.07$0.06$66.90 million$67.10 millionViewListenView Earnings Details
4/28/2016Q116$0.07$0.11$61.31 million$62.00 millionViewListenView Earnings Details
2/23/2016Q415$0.29$0.36$91.04 million$91.10 millionViewListenView Earnings Details
11/5/2015Q315$0.23$0.50$82.98 million$91.30 millionViewN/AView Earnings Details
8/6/2015Q215$0.21$0.16$74.06 million$77.60 millionViewN/AView Earnings Details
5/7/2015Q115$0.40$0.63$70.90 million$70.80 millionViewN/AView Earnings Details
3/3/2015Q414$0.44$0.53$63.50 million$66.50 millionViewN/AView Earnings Details
11/11/2014Q314$0.29$0.63$57.10 million$58.30 millionViewN/AView Earnings Details
8/12/2014Q214$0.30$0.48$52.77 million$55.70 millionViewN/AView Earnings Details
3/4/2014Q413$0.55$0.71$34.73 million$40.20 millionViewN/AView Earnings Details
11/12/2013Q3$0.33$0.58$27.00 million$29.20 millionViewListenView Earnings Details
8/13/2013Q213$0.12$0.35$15.07 million$18.80 millionViewN/AView Earnings Details
6/3/2013Q113$0.01$2.00 million$11.10 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Insys Therapeutics (NASDAQ:INSY)
Current Year EPS Consensus Estimate: $-0.62 EPS
Next Year EPS Consensus Estimate: $-0.66 EPS


Dividend History for Insys Therapeutics (NASDAQ:INSY)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Insys Therapeutics (NASDAQ:INSY)
Insider Ownership Percentage: 67.90%
Institutional Ownership Percentage: 25.44%
Insider Trades by Quarter for Insys Therapeutics (NASDAQ:INSY)
Institutional Ownership by Quarter for Insys Therapeutics (NASDAQ:INSY)
Insider Trades by Quarter for Insys Therapeutics (NASDAQ:INSY)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/11/2017John N Kapoor Trust Dated SeptMajor ShareholderBuy17,500$8.93$156,275.00View SEC Filing  
8/10/2017Saeed MotahariCEOBuy5,500$8.92$49,060.00View SEC Filing  
6/14/2017Saeed MotahariCEOBuy5,400$11.10$59,940.00View SEC Filing  
6/1/2017Rohit VishnoiDirectorBuy4,000$14.14$56,560.00View SEC Filing  
5/18/2017Steven J MeyerDirectorBuy8,000$12.21$97,680.00View SEC Filing  
5/16/2017Saeed MotahariCEOBuy4,500$11.98$53,910.00View SEC Filing  
11/4/2016Steven J MeyerDirectorBuy10,000$10.75$107,500.00View SEC Filing  
8/16/2016Theodore H StanleyDirectorSell15,000$18.02$270,300.00View SEC Filing  
8/12/2016John N Kapoor Trust Dated SeptMajor ShareholderBuy5,700$18.57$105,849.00View SEC Filing  
8/11/2016Patrick FourteauDirectorSell15,000$18.46$276,900.00View SEC Filing  
8/9/2016Daniel BrennanVPSell5,781$19.16$110,763.96View SEC Filing  
6/6/2016Theodore H StanleyDirectorSell16,000$16.27$260,320.00View SEC Filing  
5/12/2016John N Kapoor Trust Dated SeptMajor ShareholderBuy50,000$12.84$642,000.00View SEC Filing  
3/4/2016Patrick FourteauDirectorSell15,000$18.22$273,300.00View SEC Filing  
11/17/2015John N Kapoor Trust Dated SeptMajor ShareholderBuy5,000$29.50$147,500.00View SEC Filing  
11/12/2015John N Kapoor Trust Dated SeptMajor ShareholderBuy10,000$26.58$265,800.00View SEC Filing  
11/12/2015Patrick FourteauDirectorSell30,000$26.48$794,400.00View SEC Filing  
9/14/2015Theodore H. StanleyDirectorSell4,000$37.04$148,160.00View SEC Filing  
6/10/2015Fosse Franc DelGeneral CounselSell10,000$34.48$344,800.00View SEC Filing  
6/5/2015Steven J MeyerDirectorSell5,000$63.00$315,000.00View SEC Filing  
5/27/2015Brian TambiDirectorSell3,100$60.09$186,279.00View SEC Filing  
5/26/2015Brian TambiDirectorSell1,800$60.00$108,000.00View SEC Filing  
5/20/2015Patrick FourteauDirectorSell9,064$60.00$543,840.00View SEC Filing  
5/18/2015Darryl S BakerCFOSell10,000$59.17$591,700.00View SEC Filing  
5/11/2015Steven J MeyerDirectorSell18,000$57.06$1,027,080.00View SEC Filing  
3/17/2015Michael L BabichCEOSell75,000$58.63$4,397,250.00View SEC Filing  
3/11/2015Patrick FourteauDirectorSell10,000$59.94$599,400.00View SEC Filing  
3/10/2015Theodore H StanleyDirectorSell3,300$60.03$198,099.00View SEC Filing  
2/9/2015Darryl S BakerCFOSell30,000$52.23$1,566,900.00View SEC Filing  
11/19/2014Patrick FourteauDirectorSell25,000$39.11$977,750.00View SEC Filing  
11/4/2014Michael L BabichCEOSell80,000$38.66$3,092,800.00View SEC Filing  
8/13/2014Theodore H StanleyDirectorBuy3,000$33.93$101,790.00View SEC Filing  
6/16/2014John N KapoorDirectorBuy5,000$26.13$130,650.00View SEC Filing  
6/13/2014John N KapoorDirectorBuy5,000$25.44$127,200.00View SEC Filing  
6/12/2014John N KapoorDirectorBuy20,000$24.84$496,800.00View SEC Filing  
6/11/2014John N KapoorDirectorBuy20,000$24.54$490,800.00View SEC Filing  
5/19/2014Theodore StanleyDirectorBuy4,000$21.94$87,760.00View SEC Filing  
5/15/2014Patrick FourteauDirectorBuy7,500$22.77$170,775.00View SEC Filing  
3/5/2014Larry DillahaInsiderSell149,932$74.57$11,180,429.24View SEC Filing  
3/5/2014Michael BabichCEOSell288,432$74.58$21,511,258.56View SEC Filing  
1/16/2014Darryl BakerCFOSell10,000$49.61$496,100.00View SEC Filing  
1/15/2014Darryl BakerCFOSell10,000$47.54$475,400.00View SEC Filing  
1/14/2014Darryl BakerCFOSell10,000$45.64$456,400.00View SEC Filing  
12/9/2013John KapoorDirectorSell27,428$47.25$1,295,973.00View SEC Filing  
8/16/2013Michael BabichCEOBuy1,000$24.90$24,900.00View SEC Filing  
8/14/2013Patrick FourteauDirectorBuy5,000$23.77$118,850.00View SEC Filing  
6/4/2013Michael L BabichCEOBuy1,250$10.93$13,662.50View SEC Filing  
5/24/2013Pierre LapalmeDirectorBuy3,000$10.39$31,170.00View SEC Filing  
5/14/2013Patrick FourteauDirectorBuy5,000$10.90$54,500.00View SEC Filing  
5/13/2013Patrick FourteauDirectorBuy4,800$10.90$52,320.00View SEC Filing  
5/7/2013Patrick FourteauDirectorBuy50,000$8.36$418,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Insys Therapeutics (NASDAQ:INSY)
Latest Headlines for Insys Therapeutics (NASDAQ:INSY)
DateHeadline logoInsys Therapeutics, Inc. (INSY) Receives Consensus Recommendation of "Hold" from Analysts - October 18 at 4:34 AM logoETFs with exposure to INSYS Therapeutics, Inc. : October 17, 2017 - October 18 at 1:54 AM logoInsys Therapeutics (INSY) and Aduro Biotech (ADRO) Financial Contrast - October 17 at 6:46 PM logoInsys Therapeutics (INSY) Presents At Oppenheimer & Co. Specialty Pharmaceuticals Conference - Slideshow - October 13 at 2:43 AM logoInsys Therapeutics' (INSY) "Outperform" Rating Reaffirmed at Royal Bank Of Canada - October 11 at 8:02 AM logoFeatured Company News - INSYS Responds to the New Jersey Lawsuit Concerning Subsys, a Spray for Cancer Patients Containing Fentanyl - October 10 at 7:18 PM logoINSYS Therapeutics, Inc. to Participate in Oppenheimer Specialty Pharma Summit - GlobeNewswire (press release) - October 10 at 12:58 AM logoINSYS Therapeutics Extends ‘Compassionate Use’ Studies of Cannabidiol (CBD) for Refractory Pediatric Epilepsy - October 9 at 7:56 PM logoINSYS Therapeutics, Inc. to Participate in Oppenheimer Specialty Pharma Summit - October 9 at 7:56 PM logoBRIEF-Insys Therapeutics replaces 90 pct of original sales force - October 6 at 11:39 PM logoNew Jersey sues Insys as opioid maker settles with Massachusetts - Reuters - October 6 at 8:29 AM logoNew Jersey is suing Insys over its opioid sales practices - MarketWatch - October 6 at 8:29 AM logoNew Jersey Sues Drugmaker Insys Over Opioid Painkiller - October 6 at 12:35 AM logoINSYS Therapeutics, Inc.: Gathering momentum, can it sustain its performance? - October 6 at 12:35 AM logoNew Jersey is suing Insys over its opioid sales practices - October 6 at 12:35 AM logoNew Jersey sues Insys as opioid maker settles with Massachusetts - October 6 at 12:35 AM logo[$$] New Jersey Sues Insys Over Opioid Painkiller - October 6 at 12:34 AM logoContrasting Insys Therapeutics (INSY) & The Competition - October 5 at 2:26 PM logoSenvest Management shorting drug stocks Insys, Akorn, Fresenius - Reuters - October 5 at 8:44 AM logoINSYS Therapeutics Completes Pharmacokinetics (PK) Study of Intranasal Naloxone for Opioid Overdose - GlobeNewswire (press release) - October 5 at 8:44 AM logoInsys Therapeutics (INSY) Says it Completed PK Study of Intranasal Naloxone for Opioid Overdose - October 4 at 5:47 PM logoInsys faults Anthem lawsuit over opioid drug as other insurers sue - October 4 at 5:47 PM logoSohn Conference: Raising the red flag on drug makers - October 4 at 5:47 PM logoINSYS Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : INSY-US : October 3, 2017 - October 4 at 5:47 PM logoINSYS Therapeutics Completes Pharmacokinetics (PK) Study of Intranasal Naloxone for Opioid Overdose - October 4 at 5:47 PM logoWhy LiLAC Group, Insys Therapeutics, and Synchronoss Technologies Jumped Today - Motley Fool - October 2 at 11:11 PM logoThis U.S. Marijuana Stock Is Arguably the Best on the Market -- and It's Dirt Cheap - October 2 at 1:08 PM logo-$0.11 EPS Expected for Insys Therapeutics, Inc. (INSY) This Quarter - October 2 at 12:20 PM logoINSYS Therapeutics Files New Drug Application (NDA) for Buprenorphine Sublingual Spray with FDA - Nasdaq - September 29 at 10:08 PM logoINSYS Therapeutics Files New Drug Application (NDA) for Buprenorphine Sublingual Spray with FDA - September 29 at 9:23 AM logoInsys Therapeutics (INSY) Presents At Cantor Fitzgerald Global Healthcare Conference - Slideshow - September 28 at 3:53 PM logoETFs with exposure to INSYS Therapeutics, Inc. : September 25, 2017 - September 25 at 6:30 PM logoInsys Therapeutics, Inc. (INSY) Given Average Recommendation of "Hold" by Analysts - September 23 at 2:44 AM logoINSYS Therapeutics Hires First Corporate Communications Leader and New Investor Relations Agency - GlobeNewswire (press release) - September 22 at 1:39 PM logoINSYS Therapeutics to Present at Cantor Fitzgerald Global Healthcare Conference - September 22 at 1:39 PM logoINSYS Therapeutics to Present at Cantor Fitzgerald Global Healthcare Conference - September 21 at 7:14 PM logoOur 5 Top Picks For A Booming Marijuana Market - September 20 at 9:33 PM logoInsys Problems Keep Piling Up - September 18 at 7:22 PM logoExclusive: Prosecutors identify Insys founder as unindicted co-conspirator in opioid case - Reuters - September 16 at 1:56 AM logoTeva Looks to Hit Insys Where It Hurts - Seeking Alpha - September 15 at 1:18 AM logoCompany under fire for opioid marketing files patent suit - September 15 at 1:18 AM logoETFs with exposure to INSYS Therapeutics, Inc. : September 14, 2017 - September 15 at 1:18 AM logoINSYS Therapeutics, Inc. :INSY-US: Earnings Analysis: Q2, 2017 By the Numbers : September 13, 2017 - September 14 at 6:29 AM logoHave Investors Already Priced In INSYS Therapeutics Inc’s (INSY) Growth? - September 13 at 2:52 AM logoReport: Drug company faked cancer patients to sell drug - CNN - September 8 at 1:17 AM logoNemus Bioscience CEO Talks 'Waves Of Dominance' In The Cannabis Therapeutics Industry - September 7 at 8:14 PM logoSenator reveals results of opioid inquiry into Insys - September 6 at 7:53 PM logo[$$] Opioid Maker Bent Rules to Get Drug to Patients, Senate Report Says - September 6 at 7:53 PM logoU.S. senator reveals results of opioid inquiry into Insys - September 6 at 7:53 PM
News IconArizona accuses Insys of fraudulent opioid marketing scheme - September 1 at 8:30 PM



Insys Therapeutics (INSY) Chart for Wednesday, October, 18, 2017

This page was last updated on 10/18/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.